Cargando…

Reactive infectious mucocutaneous eruption – repeat etanercept after intravenous immunoglobulin: A case report

Reactive infectious mucocutaneous eruption is a recently distinguished mucosal-predominant blistering eruption triggered by respiratory infections. We describe a previously healthy 11-year-old Black female with rapidly progressive mucocutaneous blistering after prodromal respiratory infection sympto...

Descripción completa

Detalles Bibliográficos
Autores principales: Tonkin, Rochelle, Ladha, Malika, Johnson, Nicole, Astle, William F, Britton, Ami, Shear, Neil H, Murguía-Favela, Luis, Ramien, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393491/
https://www.ncbi.nlm.nih.gov/pubmed/36003890
http://dx.doi.org/10.1177/2050313X221117887
_version_ 1784771280435675136
author Tonkin, Rochelle
Ladha, Malika
Johnson, Nicole
Astle, William F
Britton, Ami
Shear, Neil H
Murguía-Favela, Luis
Ramien, Michele
author_facet Tonkin, Rochelle
Ladha, Malika
Johnson, Nicole
Astle, William F
Britton, Ami
Shear, Neil H
Murguía-Favela, Luis
Ramien, Michele
author_sort Tonkin, Rochelle
collection PubMed
description Reactive infectious mucocutaneous eruption is a recently distinguished mucosal-predominant blistering eruption triggered by respiratory infections. We describe a previously healthy 11-year-old Black female with rapidly progressive mucocutaneous blistering after prodromal respiratory infection symptoms. Reactive infectious mucocutaneous eruption was suspected and treated with systemic corticosteroids followed by etanercept. Twenty-four hours after etanercept, the diagnosis of multisystem inflammatory syndrome in children was raised and intravenous immunoglobulin was given. Rapidly worsening mucocutaneous disease ensued but was controlled by a second dose of etanercept. Our case highlights the following: (1) the novel observation of possible interaction/neutralization of etanercept by intravenous immunoglobulin, (2) the challenging differential diagnosis of multisystem inflammatory syndrome in children for reactive infectious mucocutaneous eruption patients in the Coronavirus disease 2019 (COVID-19) pandemic, and (3) the role of early treatment to prevent dyspigmentation.
format Online
Article
Text
id pubmed-9393491
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-93934912022-08-23 Reactive infectious mucocutaneous eruption – repeat etanercept after intravenous immunoglobulin: A case report Tonkin, Rochelle Ladha, Malika Johnson, Nicole Astle, William F Britton, Ami Shear, Neil H Murguía-Favela, Luis Ramien, Michele SAGE Open Med Case Rep JCMS Case Report Reactive infectious mucocutaneous eruption is a recently distinguished mucosal-predominant blistering eruption triggered by respiratory infections. We describe a previously healthy 11-year-old Black female with rapidly progressive mucocutaneous blistering after prodromal respiratory infection symptoms. Reactive infectious mucocutaneous eruption was suspected and treated with systemic corticosteroids followed by etanercept. Twenty-four hours after etanercept, the diagnosis of multisystem inflammatory syndrome in children was raised and intravenous immunoglobulin was given. Rapidly worsening mucocutaneous disease ensued but was controlled by a second dose of etanercept. Our case highlights the following: (1) the novel observation of possible interaction/neutralization of etanercept by intravenous immunoglobulin, (2) the challenging differential diagnosis of multisystem inflammatory syndrome in children for reactive infectious mucocutaneous eruption patients in the Coronavirus disease 2019 (COVID-19) pandemic, and (3) the role of early treatment to prevent dyspigmentation. SAGE Publications 2022-08-17 /pmc/articles/PMC9393491/ /pubmed/36003890 http://dx.doi.org/10.1177/2050313X221117887 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle JCMS Case Report
Tonkin, Rochelle
Ladha, Malika
Johnson, Nicole
Astle, William F
Britton, Ami
Shear, Neil H
Murguía-Favela, Luis
Ramien, Michele
Reactive infectious mucocutaneous eruption – repeat etanercept after intravenous immunoglobulin: A case report
title Reactive infectious mucocutaneous eruption – repeat etanercept after intravenous immunoglobulin: A case report
title_full Reactive infectious mucocutaneous eruption – repeat etanercept after intravenous immunoglobulin: A case report
title_fullStr Reactive infectious mucocutaneous eruption – repeat etanercept after intravenous immunoglobulin: A case report
title_full_unstemmed Reactive infectious mucocutaneous eruption – repeat etanercept after intravenous immunoglobulin: A case report
title_short Reactive infectious mucocutaneous eruption – repeat etanercept after intravenous immunoglobulin: A case report
title_sort reactive infectious mucocutaneous eruption – repeat etanercept after intravenous immunoglobulin: a case report
topic JCMS Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393491/
https://www.ncbi.nlm.nih.gov/pubmed/36003890
http://dx.doi.org/10.1177/2050313X221117887
work_keys_str_mv AT tonkinrochelle reactiveinfectiousmucocutaneouseruptionrepeatetanerceptafterintravenousimmunoglobulinacasereport
AT ladhamalika reactiveinfectiousmucocutaneouseruptionrepeatetanerceptafterintravenousimmunoglobulinacasereport
AT johnsonnicole reactiveinfectiousmucocutaneouseruptionrepeatetanerceptafterintravenousimmunoglobulinacasereport
AT astlewilliamf reactiveinfectiousmucocutaneouseruptionrepeatetanerceptafterintravenousimmunoglobulinacasereport
AT brittonami reactiveinfectiousmucocutaneouseruptionrepeatetanerceptafterintravenousimmunoglobulinacasereport
AT shearneilh reactiveinfectiousmucocutaneouseruptionrepeatetanerceptafterintravenousimmunoglobulinacasereport
AT murguiafavelaluis reactiveinfectiousmucocutaneouseruptionrepeatetanerceptafterintravenousimmunoglobulinacasereport
AT ramienmichele reactiveinfectiousmucocutaneouseruptionrepeatetanerceptafterintravenousimmunoglobulinacasereport